Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) just unveiled an announcement.
Imugene Limited has applied to the ASX for quotation of 15,077,309 new ordinary fully paid shares, with an issue date of April 24, 2026. The securities form part of a previously announced transaction, indicating an expansion of the company’s listed capital base that may affect its shareholder structure and trading liquidity.
The application, lodged as a new announcement under ASX code IMU, follows earlier disclosure via an Appendix 3B. By progressing these securities to quotation, Imugene moves to formalize the market listing of these shares, a procedural step that supports capital management and aligns with ASX listing rule requirements.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an ASX-listed biotechnology company focused on developing therapies in the healthcare sector. Its ordinary fully paid shares trade under the ticker IMU on the Australian Securities Exchange, with the company registered under ABN 99 009 179 551.
Average Trading Volume: 1,532,267
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$51.77M
Learn more about IMU stock on TipRanks’ Stock Analysis page.